Bisphenol-A glucuronidation in human liver and breast: identification of UDP-glucuronosyltransferases (UGTs) and influence of genetic polymorphisms

Xenobiotica

Volumn 47, Issue 1, 2017, Pages 1-10

  Street, Christina M ^a   Zhu, Zhaohui ^a   Finel, Moshe ^b   Court, Michael H ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Bisphenol A; breast; breast cancer; glucuronidation; liver

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MESSENGER RNA; UDP GLUCURONOSYLTRANSFERASE 2B15; UDP GLUCURONOSYLTRANSFERASE 2B4; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A10; DANGEROUS GOODS; PHENOL DERIVATIVE; UGT1A1 ENZYME;

ADULT; AGED; ALLELE; ARTICLE; BREAST; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; GLUCURONIDATION; HUMAN; HUMAN TISSUE; LIVER; LIVER MICROSOME; MALE; DANGEROUS GOODS; GENETICS; METABOLISM;

BENZHYDRYL COMPOUNDS; BREAST; GLUCURONOSYLTRANSFERASE; HAZARDOUS SUBSTANCES; HUMANS; LIVER; PHENOLS; POLYMORPHISM, GENETIC;

EID: 84961390578     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2016.1156784     Document Type: Article

References (39)

1. Adegoke OJ, Shu XO, Gao YT, et al (2004). Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res Treat 85:239–45
2. Cheng TC, Chen ST, Huang CS, et al (2005). Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes:a multigenic study on cancer susceptibility. Int J Cancer 113:345–53
3. Cheng Z, Rios GR, King CD, et al (1998). Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol Sci 45:52–7
4. Clendenen T, Zeleniuch-Jacquotte A, Wirgin I, et al (2013). Genetic variants in hormone-related genes and risk of breast cancer. PLoS One 8:e69367
5. Court MH., (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.Meth Enzymol 400:104–16
6. Court MH., (2010). Interindividual variability in hepatic drug glucuronidation:studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209–24
7. Court MH, Duan SX, Guillemette C, et al (2002). Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs):S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 30:1257–65
8. Court MH, Hao Q, Krishnaswamy S, et al (2004). UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics:UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656–65
9. Court MH, Zhang X, Ding X, et al (2012). Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42:266–77
10. Fay MJ, Nguyen MT, Snouwaert JN, et al (2015). Xenobiotic metabolism in mice lacking the UDP-glucuronosyltransferase 2 family. Drug Metab Dispos 43:1838-1846.
11. Gestl SA, Green MD, Shearer DA, et al (2002). Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. Am J Pathol 160:1467–79
12. Gibson CR, Lu P, Maciolek C, et al (2013). Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica 43:1027–36
13. Girard H, Court MH, Bernard O, et al (2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene:evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501–15
14. Girard H, Thibaudeau J, Court MH, et al (2005). UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 42:448–57
15. Gramec Skledar D, Troberg J, Lavdas J, et al (2015). Differences in the glucuronidation of bisphenols F and S between two homologous human UGT enzymes, 1A9 and 1A10. Xenobiotica 45:511–19
16. Guillemette C, De Vivo I, Hankinson SE, et al (2001). Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 10:711–14
17. Guillemette C, Millikan RC, Newman B, Housman DE., (2000). Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 60:950–6
18. Haakensen VD, Biong M, Lingjaerde OC, et al (2010). Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density. Breast Cancer Res 12:R65
19. Hanioka N, Naito T, Narimatsu S., (2008). Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 74:33–6
20. Hanioka N, Oka H, Nagaoka K, et al (2011). Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation. Arch Toxicol 85:1373–81
21. Huo D, Kim HJ, Adebamowo CA, et al (2008). Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat 110:367–76
22. Kuester RK, Sipes IG., (2007). Prediction of metabolic clearance of bisphenol A (4,4 '-dihydroxy-2,2-diphenylpropane) using cryopreserved human hepatocytes. Drug Metab Dispos 35:1910–15
23. Kurebayashi H, Okudaira K, Ohno Y., (2010). Species difference of metabolic clearance of bisphenol A using cryopreserved hepatocytes from rats, monkeys and humans. Toxicol Lett 198:210–15
24. Kurkela M, Garcia-Horsman JA, Luukkanen L, et al (2003). Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem 278:3536–44
25. Marie-Genica. (2010). Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 119:463–74
26. Rezg R, El-Fazaa S, Gharbi N, Mornagui B., (2014). Bisphenol A and human chronic diseases:current evidences, possible mechanisms, and future perspectives. Environ Int 64:83–90
27. Rhoads K, Sacco JC, Drescher N, et al (2011). Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast. Toxicol Sci 121:245–56
28. Rochester JR., (2013). Bisphenol A and human health:a review of the literature. Reprod Toxicol 42:132–55
29. Schug TT, Janesick A, Blumberg B, Heindel JJ., (2011). Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol 127:204–15
30. Shatalova EG, Loginov VI, Braga EA, et al (2006). [Association of polymorphisms in SULT1A1 and UGT1A1 genes with breast cancer risk and phenotypes in Russian women]. Mol Biol (Mosk) 40:263–70
31. Sneitz N, Court MH, Zhang X, et al (2009). Human UDP-glucuronosyltransferase UGT2A2:cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3. Pharmacogenet Genomics 19:923–34
32. Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A., (2008). Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 73:611–20
33. Sun C, Huo D, Nemesure B, et al (2012). Lack of association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer in populations of African ancestry. Int J Cancer 130:2740–2
34. Thibaudeau J, Lepine J, Tojcic J, et al (2006). Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 66:125–33
35. Trdan Lusin T, Roskar R, Mrhar A., (2012). Evaluation of bisphenol A glucuronidation according to UGT1A1*28 polymorphism by a new LC-MS/MS assay. Toxicology 292:33–41
36. Tsezou A, Tzetis M, Giannatou E, et al (2007). Genetic polymorphisms in the UGT1A1 gene and breast cancer risk in Greek women. Genet Test 11:303–6
37. Vandenberg LN, Hauser R, Marcus M, et al (2007). Human exposure to bisphenol A (BPA). Reprod Toxicol 24:139–77
38. Yamanaka H, Nakajima M, Katoh M, et al (2004). A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14:329–32
39. Yao L, Qiu LX, Yu L, et al (2010). The association between TA-repeat polymorphism in the promoter region of UGT1A1 and breast cancer risk:a meta-analysis. Breast Cancer Res Treat 122:879–82